SCYNEXIS Inc SCYX

US Pharmaceuticals

$3.58 ▲ +2.29% (+$0.08)

🎈 Low Float

Open $3.52

Prev Close $3.50

Day Range $3.45 – $3.68

52W Range $3.28 – $9.12

Market Cap $34.84M

Beta 1.29

EPS (TTM) $-2.16

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-05-02
Shares Out.	9,950,000
Website	scynexis.com/ ↗
Phone	12018845485
Employees	29
Revenue	$0
Gross Profit	$0
Net Income	-$8.5M
Free Cash Flow	-$12.1M
Total Assets	$68.0M
Total Liabilities	$8.9M
Equity	$59.0M

About SCYNEXIS Inc

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

SCYNEXIS Inc is a publicly traded company under the ticker symbol SCYX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.